A first-in-human study of DYP688, an antibody drug conjugate delivering a direct Gq/11 inhibitor, in patients with metastatic uveal melanoma (MUM) and other GNAQ/11 mutant melanomas.

作者
Matteo Salvatore Carlino,Reinhard Dummer,Tanja Gromke,Jessica C. Hassel,Ellen Kapiteijn,Damien Kee,Sophie Piperno-Neumann,Egle Ramelyte,Alexander Noor Shoushtari,Ryan Joseph Sullivan,Alexander Z. Wei,Anne-Marie Duggan,Mary Elizabeth Ising,Pedro Milanez‐Almeida,Thiruvamoor P. Ramkumar,Aimee Reynolds,Sherif Sharaby,Padmaja Yerramilli-Rao,Emiliano Calvo
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:43 (16_suppl): 9509-9509 被引量:6
标识
DOI:10.1200/jco.2025.43.16_suppl.9509
摘要

9509 Background: GNAQ/11 mutations occur in up to 95% of uveal melanomas (UM) and a subset of non-uveal melanomas. Cell surface PMEL17 (gp100) is highly and broadly expressed in melanoma (including UM). SDZ475 (FR900359) is a potent GNAQ/11 inhibitor, however in vivo toxicity has precluded clinical development. DYP688 is an antibody drug conjugate that binds to PMEL17 to deliver the payload SDZ475. Methods: This first-in-human, open-label, multicenter, single-arm study (NCT05415072) of DYP688 in patients (pts) with MUM and other GNAQ/11 mutant melanomas aimed to evaluate safety and tolerability, determine recommended dose(s) (RDs) of DYP688 (primary objective), and evaluate antitumor activity, pharmacokinetics (PK), and immunogenicity (secondary objectives). Here we present data from the ongoing Phase I dose-escalation. Results: As of 25 Oct 2024, 66 pts were treated with DYP688 at 4 (n=5), 8 (n=12), 12 (n=13), 16 (n=14), and 24 (n=11) mg/kg biweekly (Q2W) and at 12 (n=5) and 16 (n=6) mg/kg once weekly (QW) in 28-day cycles. Tumor types included MUM (n=60) and non-MUM (n=6). Of the 66 treated pts, 60 (90.9%) had prior antineoplastic therapy; 38 (57.6%) received ≥2 lines, and 22 (33.3%) received prior tebentafusp. The majority (n=57, 86.4%) of pts had liver metastases and elevated LDH (n=43, 65.25%) at baseline. Preliminary PK demonstrated a nearly dose-proportional exposure of total monoclonal antibody and active conjugated payload. Most treatment-related adverse events (TRAEs) were grade ≤2 with 4 grade 3 events: hypotension, hypercalcemia, anemia, and increased GGT. One dose limiting toxicity was reported (grade 3 hypotension at 24mg/kg Q2W). Most common TRAEs (all grades/doses, >15%) were hypercalcemia (22.7%), dry mouth (19.7%), fatigue (18.2%) and peripheral edema (16.7%). At data cutoff, 27 (40.9%) pts remained on study treatment and 39 (59.1%) pts had discontinued, mainly due to disease progression (PD) and none due to AEs. Of the 55 pts treated at doses ≥8 mg/kg Q2W who were eligible for RECIST v1.1 evaluation, confirmed objective responses were seen in 12 (21.8%) pts with 1/12 at 8 mg/kg (Q2W), 3/13 (1 complete response) at 12 mg/kg (Q2W), 5/8 at 16 mg/kg (Q2W), 2/5 at 12 mg/kg (QW) and 1/6 at 16 mg/kg (QW), with evidence of deepening response over time. Best response of PD was seen in 6/55 (10.9%) pts and stable disease in 35/55 (63.6%) pts. Median (range) duration of treatment by Kaplan Meier was 7.0 (<1 – 20.7) months. Analysis of mutational profiles from tissue and circulating tumor DNA is ongoing. Conclusions: DYP688 shows favorable safety and tolerability at all doses tested and promising preliminary clinical efficacy at doses ≥ 12mg/kg Q2W; the RDs for dose optimization are yet to be declared and dose exploration is ongoing. Clinical trial information: NCT05415072 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
徐梦曦完成签到 ,获得积分10
1秒前
Lily完成签到,获得积分10
2秒前
3秒前
3秒前
OVOV完成签到,获得积分10
4秒前
无尘完成签到 ,获得积分0
4秒前
修勾想要干饭咧完成签到,获得积分10
4秒前
lxm发布了新的文献求助10
4秒前
dunphy完成签到 ,获得积分10
4秒前
ASCC完成签到 ,获得积分10
4秒前
5秒前
5秒前
linhongwei发布了新的文献求助20
7秒前
企鹅发布了新的文献求助10
7秒前
伶俐的高烽完成签到,获得积分10
8秒前
liangchao发布了新的文献求助10
8秒前
笑点低明杰完成签到,获得积分10
9秒前
苹果完成签到 ,获得积分10
9秒前
11秒前
11秒前
天天快乐的应助被科研通管家采纳,获得10
11秒前
科目三的应助被科研通管家采纳,获得10
11秒前
ding的应助被科研通管家采纳,获得10
11秒前
midshady的应助被科研通管家采纳,获得10
11秒前
11秒前
11秒前
领导范儿的应助被可爱安荷采纳,获得10
11秒前
bkagyin的应助被科研通管家采纳,获得10
11秒前
ding的应助被科研通管家采纳,获得10
11秒前
orixero的应助被科研通管家采纳,获得10
12秒前
12秒前
SciGPT的应助被科研通管家采纳,获得10
12秒前
上官若男的应助被科研通管家采纳,获得10
12秒前
汉堡包的应助被科研通管家采纳,获得10
12秒前
NexusExplorer的应助被科研通管家采纳,获得10
12秒前
科视完成签到,获得积分10
12秒前
彭于晏的应助被科研通管家采纳,获得10
12秒前
喝口可乐的应助被科研通管家采纳,获得10
12秒前
桐桐的应助被科研通管家采纳,获得10
12秒前
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190478
求助须知:如何正确求助?哪些是违规求助? 9577686
关于积分的说明 21853808
捐赠科研通 7789496
什么是DOI,文献DOI怎么找? 3436407
关于科研通互助平台的介绍 2560235
邀请新用户注册赠送积分活动 2483054